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at www.jvascsurg.org.DISCUSSIONDr Jon Matsumura (Madison, Wisc). What other process
measures were in place to address wound complications during
the study? Methicillin-resistant Staphylococcus aureus screening,
normothermia, antibiotic selection and timing?
Dr C. Keith Ozaki. Over the last decade, we have had many
changes and redesign of our care processes to address these issues.
More attention to normothermia, more attention to timely periop-
erative antibiotics, increased considerations of approaches, such as
skip incisions, all of those continued to be implemented over time
and may account for some of the differences between the current
report and the prior nonconcurrent study that had the original
control group ﬁrst and then at a later date had the silver alginate
dressing cohort.
There were a variety of wound practices at these three
different institutions, so I cannot summarize those in just a few
statements. But we did try to design this trial to be applicable to
several different settings, both the civilian and the Veterans Admin-
istration population.Dr Peter Lawrence (Los Angeles, Calif). Did you classify
wounds by degree of contamination? Clean contaminated wounds
in patients with foot infections might beneﬁt from this dressing,
while the average clean wound would not. Did you calculate the
cost/beneﬁt for each group?
Dr Ozaki. That is an excellent point. The cost data related to
this, especially the cost of having a wound complication, will be pre-
sented at Eastern Vascular and New England meetings this fall.
These dressings are actually quite inexpensive. For a 4-by-5 inch
piece, the actual General Services Administration price, and that
translates pretty well to the civilian price, is less than $10.00. We
tested an approach that we thought might be cost-effective even if
there was a very small clinical beneﬁt. Whenever we broke the cases
down into those that were nonclean, we actually by c2 analysis did
see a statistically signiﬁcant beneﬁt for the silver dressing. I did not
present those data though because I do not trust the data. Half of
those caseswere labeled as clean-contaminated.Andby the technical
deﬁnition, that means you either enter a hollow viscus or you have a
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quality of that information.
But you are correct, from our data set we should be able to
select patients most at risk, and maybe for that select population
there could be a role for this type of dressing.
Dr David Yu (Seattle, Wash). I was wondering if the immu-
nocompetence status of these patients were taken into consider-
ation for the study?
Dr Ozaki. I do not have any speciﬁc assays of immune status.
We did have a subset of the patients that were on immunosuppres-
sive prednisone, and there was no differential in the wound compli-
cation rates for these patients.
Dr Jens Eldrup-Jorgensen (Portland, Me). Surgical site in-
fections in our institution have received a lot of scrutiny of late.
I think a lot of the value of this study is to give us a contemporary
assessment of what realistic surgical site infection rates are. We ﬁnd
that in our institution they are very similar to what you are report-
ing here, and yet the expectation is that they should be much
lower, at least from some parties.
We have also tried using a silver-based dressing on a more
empiric approach. And now with the failure of this to show any ef-
ﬁcacy, are you trialing the negative-pressure dressings in some of
these more complex wounds?
Dr Ozaki. Based on some of the earlier reports, I am
intrigued by the negative-pressure dressings even for the closed in-
cisions. That technique warrants further investigation. Actual
infection rates are in the midteens for our lower extremity revascu-
larizations and 6.6% when you have to cut down to do an endovas-
cular aneurysm repair. I think that is useful data, and I think it is
real. All our study institutions had these rates.Dr Cassius Iyad Ochoa Chaar (New Haven, Conn). I
congratulate you on doing a study that is sponsored by industry
but still have data independently analyzed with the investiga-
tors. What were the lengths of those incisions, and were the
anatomical locations comparable in both groups? And for the
groin speciﬁcally, were you able to compare vertical and trans-
verse incisions?
Dr Ozaki. The average incision length was just over 32 cm.
There was not a difference between the groups in incision
length. Regarding the orientation of the groin incision, there
were many confounding factors, such as whether this was a
redo surgery that had a prior vertical incision, whether this
was an obese patient, etc. Most of the endovascular aneurysm
repair participants had a transverse groin incision vs those
with extensive occlusive disease that needed a long profundo-
plasty might have had vertical. So I am nervous about analyzing
that data under these study conditions because of those con-
founding factors. However we do have a lot of granularity in
the data set with regards to location of incisions, types of inci-
sions, and there will be future analyses of those issues.
Dr Palma Shaw (Syracuse, NY). Given the number of
different silver dressings, with different amounts of silver in each
dressing, do you think that there is a role for looking at different
amounts of silver and seeing if this has an effect?
Dr Ozaki. Yes, that is a great point. There are a variety of sil-
ver dressing products. If you talk to another silver dressing manu-
facturer, they will suggest that the reason your study was negative
is because you used the wrong dressing. If there are any industry
partners out there thirsty to really look at this, we are anxious to
have something that will help these patients.
